# A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)

> **NCT06909214** · PHASE4 · RECRUITING · sponsor: **argenx** · enrollment: 30 (estimated)

## Conditions studied

- New Onset Generalized Myasthenia Gravis (gMG)

## Interventions

- **BIOLOGICAL:** Efgartigimod PH20 SC

## Key facts

- **NCT ID:** NCT06909214
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-17
- **Primary completion:** 2026-08
- **Final completion:** 2027-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06909214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06909214, "A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06909214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*